Safety and feasibility of treatment simplification to atazanavir/ ritonavir1lamivudine in hiv-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors1atazanavir/ ritonavir with virological suppression (atazanavir and lamivudine for treatment simplification, atlas pilot study)

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 6, 2013, Pages 1364-1372

  Giambenedetto, Simona Di ^a   Fabbiani, Massimiliano ^a   Colafigli, Manuela ^a   Ciccarelli, Nicoletta ^a   Farina, Salvatore ^b   Sidella, Letizia ^a   D'Avino, Alessandro ^a   Mondi, Annalisa ^a   Cingolani, Antonella ^a   Tamburrini, Enrica ^a   Murri, Rita ^a   Navarra, Pierluigi ^a   Cauda, Roberto ^a   Luca, Andrea De ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Combined antiretroviral therapy; Dual therapy; Long term tolerability; Switch

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; BILIRUBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; VIRUS RNA;

ADULT; AMYLASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY FAT; BONE DENSITY; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COGNITION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESISTANCE; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HEALTH STATUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSIVE CRISIS; KIDNEY COLIC; MENTAL HEALTH; PATIENT COMPLIANCE; PREGNANCY; QUALITY OF LIFE; SIDE EFFECT; TREATMENT FAILURE; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS INHIBITION;

COMBINED ANTIRETROVIRAL THERAPY; DUAL THERAPY; LONG-TERM TOLERABILITY; SWITCH;

ADIPOSITY; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY COMPOSITION; BONE AND BONES; COGNITION; DRUG RESISTANCE, VIRAL; ENDPOINT DETERMINATION; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OLIGOPEPTIDES; PATIENT COMPLIANCE; PILOT PROJECTS; PREGNANCY; PYRIDINES; QUALITY OF LIFE; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; TREATMENT FAILURE;

EID: 84885150446     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt007     Document Type: Article

References (52)

1. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27-34.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services; March 27, 2012. http:// www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf (21 November 2012, date last accessed).
3. European AIDS Clinical Society (EACS). Guidelines: Clinical Management and Treatment of HIV Infected Adults in Europe, Prevention and Management of Non-Infectious Comorbidities in HIV, Version 6.1, November 2012. http://www.europeanaidsclinicalsociety.org/images/stories/ EACS-Pdf/EACSGuidelines-v6.1-English-Nov2012.pdf (21 November 2012, date last accessed).
4. British HIV Association. British HIV Association Guidelines for the Treatment of HIV-1-Positive Adults With Antiretroviral Therapy 2012. http://www.bhiva.org/documents/Guidelines/Treatment/2012/hiv1029_2.pdf (21 November 2012, date last accessed).
5. Linee Guida Italiane sull' Utilizzo dei Farmaci Antiretrovirali e sulla Gestione Diagnostico-clinica delle Persone con Infezione da HIV-1, Luglio 2012. http://www.salute.gov.it/imgs/C_17_pubblicazioni_1793_allegato.pdf (21 November 2012, date last accessed).
6. Bierman WF, van Agtmael MA, Nijhuis M, et al. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 2009; 23: 279-91.
7. Arribas JR, Pulido F, Delgado R, et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr 2005; 40: 280-7.
8. Pulido F, Arribas JR, Delgado R, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 2008; 22: F1-9.
9. Saumoy M, Tiraboschi J, Gutierrez M, et al. Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study). HIV Med 2011; 12: 438-41.
10. Katlama C, Valantin MA, Algarte-Genin M, et al. Efficacy of darunavir/ ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 2010; 24: 2365-74.
11. Arribas JR, Horban A, Gerstoft J, et al. The MONET trial: darunavir/ ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 2010; 24: 223-30.
12. Arribas J, Clumeck N, Nelson M, et al. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load ,50 HIV-1 RNA copies/mL at baseline. HIV Med 2012; 13: 398-405.
13. Vernazza P, Daneel S, SchifferVet al. The role ofcompartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS 2007; 21: 1309-15.
14. Wilkin TJ, McKinnon JE, DiRienzo AG, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. J Infect Dis 2009; 199: 866-71.
15. Karlström O, Josephson F, Sönnerborg A. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. J Acquir Immune Defic Syndr 2007; 44: 417-22.
16. Pulido F, Serrano O, Rivero A, et al. Atazanavir/ritonavir monotherapy for maintenance of virologic suppression: 48 week primary analysis of the 96 week multicenter, open-label, single-arm, pilot OREY study. In: Abstracts of the Twelfth EACS Conference, Cologne, Germany, 2009. Oral PS4/6.
17. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010; 53: 323-32.
18. Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011; 154: 445-56.
19. Johnson VA, Calvez V, Günthard HF, et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011; 19: 156-64.
20. Colonno R, Rose R, McLaren C, et al. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis 2004; 189: 1802-10.
21. Yanchunas J Jr, Langley DR, Tao L, et al. Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors. Antimicrob Agents Chemother 2005; 49: 3825-32.
22. Naeger LK, Margot NA, Miller MD. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudineassociated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication. Antivir Ther 2001; 6: 115-26.
23. Kuritzkes DR, Quinn JB, Benoit SL, et al. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 1996; 10: 975-81.
24. Miller MD, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 2004; 189: 837-46.
25. Division of AIDS (DAIDS). Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. Publish Date: December, 2004. http://www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/ Documents/daidsaegradingtable.pdf (21 November 2012, date last accessed).
26. Gonzalez de Requena D, Bonora S, Canta F, et al. Atazanavir Ctrough is associated with efficacy and safety: definition of therapeutic range. In: Abstracts of the Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 2005. Abstract 645. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
27. Fabbiani M, Di Giambenedetto S, Ragazzoni E, et al. Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. HIV Med 2010; 11: 326-33.
28. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130: 461-70.
29. Fabbiani M, Di Giambenedetto S, Bracciale L, et al. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. J Antimicrob Chemother 2009; 64: 109-17.
30. Murri R, Cingolani A, De Luca A, et al. Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy. J Acquir Immune Defic Syndr 2010; 55: 411-2.
31. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001; 28: 445-9.
32. Bartels C, Wegrzyn M, Wiedl A, et al. Practice effects in healthy adults: a longitudinal study on frequent repetitive cognitive testing. BMC Neurosci 2010; 11: 118.
33. Fabbiani M, Ciccarelli N, Tana M, et al. Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients. HIV Med 2012; doi:10.1111/j. 1468-1293.2012.01044.x.
34. Grima P, Fabbiani M, Ciccarelli N, et al. Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. J Infect 2012; 65: 439-46.
35. Fabbiani M, Bracciale L, Doino M, et al. Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients. J Infect 2011; 62: 319-21.
36. Chan-Tack KM, Truffa MM, Struble KA, et al. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System. AIDS 2007; 21: 1215-8.
37. Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 2011; 204: 1191-201.
38. Giuntini R, Martinelli C, Ricci E, et al. Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study. HIV Med 2010; 11: 40-5.
39. D'Arminio Monforte A, Reiss P, Ryom L, et al. ATV-containing ART is not associated with an increased risk of cardio- or cerebro-vascular events in the D:A:D Study. In: Abstracts of the Nineteenth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 2012. Abstract 823. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
40. Fabbiani M, Bracciale L, Doino M, et al. Lipid-lowering effect of tenofovir in HIV-infected patients. J Antimicrob Chemother 2011; 66: 682-3.
41. Tungsiripat M, Kitch D, Glesby MJ, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS 2010; 24: 1781-4.
42. Randell PA, Jackson AG, Zhong L, et al. The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers. Antivir Ther 2010; 15: 227-33.
43. Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavirritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48: 2091-6.
44. Borderi M, Gibellini D, Vescini F, et al. Metabolic bone disease in HIV infection. AIDS 2009; 23: 1297-310.
45. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011; 203: 1791-801.
46. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201: 318-30.
47. Dao CN, Patel P, Overton ET, et al. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis 2011; 52: 396-405.
48. Yin M, Stein E. The effect of antiretrovirals on vitamin D. Clin Infect Dis 2011; 52: 406-8.
49. Moyle GJ, Sabin CA, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20: 2043-50.
50. Ananworanich J, Nuesch R, CôtéHC, et al. Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/ lamivudine-a Staccato trial substudy. J Antimicrob Chemother 2008; 61: 1340-3.
51. Gerschenson M, Kim C, Berzins B, et al. Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen. J Antimicrob Chemother 2009; 63: 1244-50.
52. Curran A, Martinez E, Podzamczer D, et al. Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial. Antivir Ther 2012; 17: 711-8.